---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-270370"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T21:52:45.010224+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioMarin CEO Jean-Jacques Bienaimé retiring; Alexander Hardy appointed new CEO

## Summary
- Jean-Jacques Bienaimé retires as President, CEO and Chairman on Nov 30, 2023; remains on board until 2024 annual meeting.
- Alexander Hardy (ex-Genentech CEO) becomes President and CEO and joins board effective Dec 1, 2023.
- Hardy receives $1,050,000 annual base salary, $900,000 signing bonus, and ~$15.5M in equity grants with multi-year vesting.
- Bienaimé eligible for 2023 bonus at 120% of base salary if he remains director/consultant; consulting pays $146k/mo then $73k/mo.
- Lead independent director Richard A. Meier becomes Board Chair effective Dec 1, 2023.

## SEC filing metadata
- accession: 0001193125-23-270370
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/0001193125-23-270370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/d578678d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-270370
- JSON: https://secwatch.observer/filing/0001193125-23-270370.json
- Plain text: https://secwatch.observer/filing/0001193125-23-270370.txt

## Key facts
- Executive change
  Richard A. Meier was appointed as Chair of the Board at BIOMARIN PHARMACEUTICAL INC.
  - Action: appointed
  - Role: Chair of the Board
  source text: Richard A. Meier, BioMarin’s lead independent director, will assume the role of Chair of the Board, effective December 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/0001193125-23-270370-index.htm
- Executive change
  Jean-Jacques Bienaimé retired as President, Chairman and Chief Executive Officer at BIOMARIN PHARMACEUTICAL INC.
  - Action: retired
  - Role: President, Chairman and Chief Executive Officer
  source text: Jean-Jacques Bienaimé will retire as the Company’s President, Chairman and Chief Executive Officer effective as of close of business on November 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/0001193125-23-270370-index.htm
- Executive change
  Alexander Hardy was appointed as President and Chief Executive Officer at BIOMARIN PHARMACEUTICAL INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Company announced the appointment of Alexander Hardy, age 55, to serve as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of December 1, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/0001193125-23-270370-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.